To assess glycemic outcomes during non-adjunctive use of a Medtronic continuous glucose monitoring system, CareLink™ personal software data were analyzed after insulin bolus delivery to correct hyperglycemia.
Voluntarily uploaded data captured between January 1, 2015-August 12, 2016, from European users of the MiniMed™ Veo™ insulin pump with SmartGuard™ technology, were de-identified and analyzed. Non-adjunctive sensor glucose (SG) values were defined as manually-entered self-monitored blood glucose (SMBG) values that were within ±5mg/dL of the preceding SG value. Non-adjunct vs. adjunct performance of the system in frequent non-adjunct users (at least, 10% non-adjunct use) was evaluated based on the frequency of post-corrective bolus hypoglycemia (nadir) and hyperglycemia (peak) over the 4 hours following insulin bolus delivery. All statistics were conducted per patient and analyzed using Wilcoxon signed rank test.
Among 23,784 total users, 5,851 were identified as frequent non-adjunct users. Of the over 1.7 million corrective boluses evaluated, 32% met the non-adjunctive criteria. Outcomes results are presented in the Table below.
B. Jiang: None. S. Soleymani: Employee; Self; Medtronic MiniMed, Inc. R. Vigersky: Employee; Self; Medtronic MiniMed, Inc.. A. Sullivan: None. Y. Zhong: None. P. Agrawal: None. F.R. Kaufman: Employee; Self; Medtronic.